United Therapeutics Stock Math Operators Price Series Multiplication

UTHR Stock  USD 536.12  3.30  0.62%   
The math operators module provides an execution environment for Price Series Multiplication operator and related indicators on United Therapeutics and Biogen Inc. The focus on relative price relationships between United Therapeutics and Biogen Inc helps organize trend, volatility, and risk context for United Therapeutics and Biogen Inc.

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. United Therapeutics Price Series Multiplication is a cross multiplication of United Therapeutics price series and its benchmark/peer.

United Therapeutics Technical Analysis Modules

Most technical analysis of United Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for United from various momentum indicators to cycle indicators. When you analyze United charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 965 people. As a large-cap equity, United Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 23.49, P/B of 3.29, profit margin of 41.94%. United Therapeutics has a market cap of 23.5 B, P/E of 23.49, ROE of 19.72%.

Methodology

Unless otherwise specified, financial data for United Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. United (USA Stocks:UTHR) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for United Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

United Therapeutics is covered by 14 analysts. 7 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, UBS Investment Research, Bank of America Securities, RBC Capital Markets, Jefferies, J.P. Morgan, Morgan Stanley, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board

Be your own money manager

Tracking United Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Generate Optimal Portfolios

Align your risk and return expectations

By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.

Additional Tools for United Stock Analysis

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon